TYME Technologies appoints Richie Cunningham as CEO alongside Steve Hoffman remaining Board Chairman and CSO

– USA, NJ –  Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, today announced the appointment of Richie Cunningham, former Icagen CEO, and Boehringer Ingelheim executive as CEO, effective November 24, 2020, succeeding Steve Hoffman who will remain Board Chairman and CSO, after a successful tenure as CEO since 2015.…